CL2017000792A1 - Derivados del ácido borónico - Google Patents

Derivados del ácido borónico

Info

Publication number
CL2017000792A1
CL2017000792A1 CL2017000792A CL2017000792A CL2017000792A1 CL 2017000792 A1 CL2017000792 A1 CL 2017000792A1 CL 2017000792 A CL2017000792 A CL 2017000792A CL 2017000792 A CL2017000792 A CL 2017000792A CL 2017000792 A1 CL2017000792 A1 CL 2017000792A1
Authority
CL
Chile
Prior art keywords
acid derivatives
boronic acid
malignities
lmp
hematological
Prior art date
Application number
CL2017000792A
Other languages
English (en)
Spanish (es)
Inventor
Markus Klein
Oliver Schadt
Philipp Haselmayer
Mireille Krier
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CL2017000792A1 publication Critical patent/CL2017000792A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CL2017000792A 2014-10-01 2017-03-31 Derivados del ácido borónico CL2017000792A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14003389 2014-10-01

Publications (1)

Publication Number Publication Date
CL2017000792A1 true CL2017000792A1 (es) 2017-11-10

Family

ID=51751859

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000792A CL2017000792A1 (es) 2014-10-01 2017-03-31 Derivados del ácido borónico

Country Status (21)

Country Link
US (1) US10669289B2 (enExample)
EP (1) EP3201206B1 (enExample)
JP (1) JP6662865B2 (enExample)
KR (1) KR102457840B1 (enExample)
CN (1) CN107001391B (enExample)
AU (1) AU2015327345B9 (enExample)
BR (1) BR112017006622A2 (enExample)
CA (1) CA2963203A1 (enExample)
CL (1) CL2017000792A1 (enExample)
DK (1) DK3201206T3 (enExample)
ES (1) ES2761774T3 (enExample)
IL (1) IL251302B (enExample)
MX (1) MX372823B (enExample)
MY (1) MY186911A (enExample)
NZ (1) NZ730981A (enExample)
PH (1) PH12017500293A1 (enExample)
RU (1) RU2717558C2 (enExample)
SG (1) SG11201702628XA (enExample)
UA (1) UA122672C2 (enExample)
WO (1) WO2016050358A1 (enExample)
ZA (1) ZA201703007B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053247B2 (en) 2014-10-01 2021-07-06 Bristol-Myers Squibb Company Pyrimidinones as factor XIA inhibitors

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3201208B1 (en) 2014-10-01 2021-03-24 Merck Patent GmbH Boronic acid derivatives
US10294246B2 (en) 2014-10-01 2019-05-21 Merck Patent Gmbh Substituted boronic acids and boronate esters as immunoproteasome inhibitors
EP3201205B1 (en) 2014-10-01 2020-05-13 Merck Patent GmbH Boronic acid derivatives
PT3571208T (pt) 2017-01-18 2021-04-13 Principia Biopharma Inc Inibidores do imunoproteassoma
US11274109B2 (en) 2017-08-24 2022-03-15 Merck Patent Gmbh Boronic acid derivatives
WO2019042301A1 (zh) * 2017-08-29 2019-03-07 浙江海正药业股份有限公司 (E)-α,β-不饱和酰胺化合物及其制备方法和用途
EP3694528A4 (en) * 2017-10-13 2021-07-28 The Regents of the University of California MTORC1 MODULATORS
EP3710458B1 (en) * 2017-11-16 2026-03-25 Principia Biopharma Inc. Immunoproteasome inhibitors
ES2928787T3 (es) * 2017-11-16 2022-11-22 Principia Biopharma Inc Inhibidores del inmunoproteasoma
IL280376B2 (en) 2018-07-26 2024-08-01 Merck Patent Gmbh Boronic acid derivatives, their preparation and pharmaceutical compositions containing them
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
CN113135943A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
EP4377324A1 (en) 2021-07-29 2024-06-05 Merck Patent GmbH Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7- oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain
US20240425529A1 (en) * 2021-10-14 2024-12-26 Shouyao Holdings (beijing) Co., Ltd. Boric acid derivative
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658885A (en) * 1993-04-27 1997-08-19 The Dupont Merck Pharmaceutical Company Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US5462964A (en) * 1993-10-20 1995-10-31 The Du Pont Merck Pharmaceutical Company Dipeptide boronic acid inhibitors of trypsin-like enzymes
AU5920400A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
BR0314450A (pt) * 2002-09-09 2005-07-26 Trigen Ltd Sais de ácido borÈnico com adição de uma base farmaceuticamente aceitável, formulação farmacêutica, e uso dos referidos sais para preparar uma formulação farmacêutica
UA88771C2 (ru) * 2003-08-14 2009-11-25 Сефалон, Инк. Ингибиторы протеасомы и способ их применения (варианты)
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
SG10201503168VA (en) 2010-04-22 2015-06-29 Mars Inc Inhibitors of arginase and their therapeutic applications
SG11201403254QA (en) 2011-12-22 2014-07-30 Ares Trading Sa Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors
SG10201908467RA (en) 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
MX2017004298A (es) 2014-10-01 2017-07-19 Janssen Pharmaceuticals Inc Indoles mono o disustituidos como inhibidores de la replicacion del virus del denge.
US10294246B2 (en) 2014-10-01 2019-05-21 Merck Patent Gmbh Substituted boronic acids and boronate esters as immunoproteasome inhibitors
EP3201208B1 (en) 2014-10-01 2021-03-24 Merck Patent GmbH Boronic acid derivatives
ME03360B (me) 2014-10-01 2019-10-20 Janssen Pharmaceuticals Inc Mono- ili di-supsтituisani derivaтi indola као inhibiтori replikacije virusa denge
EP3201205B1 (en) 2014-10-01 2020-05-13 Merck Patent GmbH Boronic acid derivatives
NO2721243T3 (enExample) 2014-10-01 2018-10-20

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11053247B2 (en) 2014-10-01 2021-07-06 Bristol-Myers Squibb Company Pyrimidinones as factor XIA inhibitors
US12428421B2 (en) 2014-10-01 2025-09-30 Bristol-Myers Squibb Company Pyrimidinones as factor XIA inhibitors

Also Published As

Publication number Publication date
IL251302A0 (en) 2017-05-29
BR112017006622A2 (pt) 2018-07-03
DK3201206T3 (da) 2019-12-16
MY186911A (en) 2021-08-26
JP2017531646A (ja) 2017-10-26
AU2015327345B9 (en) 2020-06-18
KR20170067802A (ko) 2017-06-16
NZ730981A (en) 2024-01-26
AU2015327345B2 (en) 2019-12-05
ES2761774T3 (es) 2020-05-21
KR102457840B1 (ko) 2022-10-21
RU2017115192A3 (enExample) 2019-03-26
AU2015327345A1 (en) 2017-05-18
WO2016050358A1 (en) 2016-04-07
EP3201206A1 (en) 2017-08-09
JP6662865B2 (ja) 2020-03-11
IL251302B (en) 2020-03-31
RU2017115192A (ru) 2018-11-06
CA2963203A1 (en) 2016-04-07
US20180179232A1 (en) 2018-06-28
ZA201703007B (en) 2022-05-25
US10669289B2 (en) 2020-06-02
RU2717558C2 (ru) 2020-03-24
MX2017003999A (es) 2018-02-09
UA122672C2 (uk) 2020-12-28
CN107001391A (zh) 2017-08-01
MX372823B (es) 2020-07-03
PH12017500293A1 (en) 2017-06-28
SG11201702628XA (en) 2017-04-27
CN107001391B (zh) 2020-11-27
EP3201206B1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
CL2017000792A1 (es) Derivados del ácido borónico
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CL2017003404A1 (es) Compuestos antibacterianos
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
CU24419B1 (es) 2-(morfolin-4-il)-1,7-naftiridinas útiles en el tratamiento o la profilaxis de enfermedades hiperproliferativas
GEAP201814288A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
LT3190113T (lt) Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai
EA201691916A1 (ru) Биарильные ингибиторы киназы
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX378288B (es) Inhibidores de pirimidina del fgfr4.
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
AR095075A1 (es) Acoplamiento electroquímico de anilinas
MX2017004037A (es) Derivados de acido boronico.
MX2017004043A (es) Derivados de acido boronico.
MX2017004046A (es) Derivados de acido boronico.
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
MX2017004655A (es) Compuestos de hidroxil purinas y aplicaciones de estos.
CL2016001623A1 (es) Compuestos de benzamida y nicotinamida y métodos para usar los mismos.
CL2017000151A1 (es) Derivados de piridona